Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

crizotinib

AstraZeneca AZ

AZ’s soon-to-be lung cancer blockbuster Tagrisso approved in Japan

Japanese regulator clears the drug for first-line use in NSCLC

The European Medicines Agency: PRIME’d for access?

Leela Barham examines the impact of the EMA's PRIME fast track system after two years

- PMLiVE

Roche’s Alecensa backed by China’s National Drug Administration

Approved to treat ALK-positive lung cancer

Roche's Perjeta pertuzumab

Daily Brief: Biosimilar Herceptin can’t make Perjeta cost effective and more

E-cigarettes can save lives - Teva gains approval for EpiPen generic

- PMLiVE

Pfizer signs mRNA flu vaccine deal with BioNTech

Pharma giant will take on development and commercial responsibility for candidates

- PMLiVE

Daily Brief: DeepMind and NHS success in AI, Bayer invests in COPD, Alecensa OK in Scotland

The latest from pharma, biotech and healthcare

- PMLiVE

FDA gives breakthrough status to Xolair for food allergies

Food allergies could open up big new market for biologic

- PMLiVE

Daily Brief: Karuna raises $42m for novel CNS approach, Chen exits Roche, Orchard gains GSK board member

The latest from pharma, biotech and healthcare

- PMLiVE

EMA cuts back as Brexit staff losses top expectations

Regulator says it faces loss of 30% of staff

- PMLiVE

Pfizer CEO reckons rebates will disappear, and that’s a positive

The move also has the support of FDA Commissioner Scott Gottlieb

Celgene building

Celgene’s Revlimid gets a win in late-stage lymphoma

Patients on Revlimid and Roche’s Rituxan saw boosted PFS rates

- PMLiVE

Novartis follows Pfizer and freezes US prices this year

And still expects revenues to come in at the high end of expectations for 2018

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links